Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy.

Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE.

J Urol. 2018 Aug 21. pii: S0022-5347(18)43729-9. doi: 10.1016/j.juro.2018.08.043. [Epub ahead of print]

PMID:
30142318
2.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR III) Group.

J Urol. 2018 Aug 2. pii: S0022-5347(18)43643-9. doi: 10.1016/j.juro.2018.05.164. [Epub ahead of print] Review.

PMID:
30077557
3.

Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center.

Salmasi A, Faiena I, Wu J, Sisk AE Jr, Sachveda A, Vandel JJ, Chamie K, Marks LS, Reiter RE.

Urol Oncol. 2018 Jul 28. pii: S1078-1439(18)30206-0. doi: 10.1016/j.urolonc.2018.06.006. [Epub ahead of print]

PMID:
30064933
4.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19.

5.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
6.

3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.

Asvadi NH, Afshari Mirak S, Mohammadian Bajgiran A, Khoshnoodi P, Wibulpolprasert P, Margolis D, Sisk A, Reiter RE, Raman SS.

Abdom Radiol (NY). 2018 May 3. doi: 10.1007/s00261-018-1598-9. [Epub ahead of print]

PMID:
29725743
7.

Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning.

Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.

J Nucl Med. 2018 Apr 13. pii: jnumed.118.209387. doi: 10.2967/jnumed.118.209387. [Epub ahead of print]

PMID:
29653978
8.

Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.

Zettlitz KA, Tsai WK, Knowles SM, Kobayashi N, Donahue TR, Reiter RE, Wu AM.

J Nucl Med. 2018 Sep;59(9):1398-1405. doi: 10.2967/jnumed.117.207332. Epub 2018 Mar 30.

PMID:
29602820
9.

Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.

Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP.

J Nucl Med. 2018 Sep;59(9):1392-1397. doi: 10.2967/jnumed.118.207704. Epub 2018 Mar 30.

PMID:
29602819
10.

A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.

Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE Jr, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE.

J Urol. 2018 Mar 7. pii: S0022-5347(18)42488-3. doi: 10.1016/j.juro.2018.03.004. [Epub ahead of print]

PMID:
29524506
11.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

12.

Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate.

Nagarajan MB, Raman SS, Lo P, Lin WC, Khoshnoodi P, Sayre JW, Ramakrishna B, Ahuja P, Huang J, Margolis DJA, Lu DSK, Reiter RE, Goldin JG, Brown MS, Enzmann DR.

Abdom Radiol (NY). 2018 Sep;43(9):2487-2496. doi: 10.1007/s00261-018-1495-2.

PMID:
29460041
13.

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.

Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ.

Oncoimmunology. 2017 Oct 16;7(2):e1380764. doi: 10.1080/2162402X.2017.1380764. eCollection 2018.

14.

Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.

Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K.

J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14.

15.

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.

PMID:
29206995
16.

Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.

Tan N, Shen L, Khoshnoodi P, Alcalá HE, Yu W, Hsu W, Reiter RE, Lu DY, Raman SS.

J Urol. 2018 May;199(5):1218-1223. doi: 10.1016/j.juro.2017.10.042. Epub 2017 Nov 8.

PMID:
29128577
17.

Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer.

Donin NM, Reiter RE.

J Nucl Med. 2018 Feb;59(2):177-182. doi: 10.2967/jnumed.117.191874. Epub 2017 Oct 6.

PMID:
28986509
18.

Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy.

Nassiri N, Chang E, Lieu P, Priester AM, Margolis DJA, Huang J, Reiter RE, Dorey FJ, Marks LS, Natarajan S.

J Urol. 2018 Feb;199(2):453-458. doi: 10.1016/j.juro.2017.08.085. Epub 2017 Aug 19.

PMID:
28830754
19.

Multi-parametric magnetic resonance imaging as a management decision tool.

Johnson DC, Reiter RE.

Transl Androl Urol. 2017 Jun;6(3):472-482. doi: 10.21037/tau.2017.05.22. Review.

20.

Anatomic and Molecular Imaging in Prostate Cancer.

Miller ET, Salmasi A, Reiter RE.

Cold Spring Harb Perspect Med. 2018 Mar 1;8(3). pii: a030619. doi: 10.1101/cshperspect.a030619. Review.

PMID:
28710256

Supplemental Content

Loading ...
Support Center